Dr. Padmaja N. Kandula, MD

Dr. Kandula practices at Columbia University Irving Medical Center in New York, New York.

Dr. Kandula's NPI, 1205056447, was assigned on April 30, 2007. Dr. Kandula graduated from Northeast Ohio Medical University in 1999. Dr. Kandula holds New York license 228823.

Dr. Kandula's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 305-4920.

Dr. Kandula's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Kandula is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Kandula to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kandula practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kandula's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kandula is board certified in clinical neurophysiology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Kandula's licenses on file in 3 states: New York, Florida and Ohio.

Dmand AI lists cerebrovascular disease, epilepsy and seizures among the conditions Dr. Kandula treats.

CMS data shows 735 Medicare services from Dr. Kandula across 10 procedure codes in 2024, for 264 Medicare patients. Medicare paid $56,408 for them.

CMS counts 264 Medicare patients who saw Dr. Kandula in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 24% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kandula's median patient age at 52, with 59% women.

In 2024, Dr. Kandula wrote 676 Medicare Part D claims for 127 patients. 92% of them were for generic drugs. CMS names the drug for 550 of them, across 12 drugs with 11 or more claims each, at $28,298 in total drug cost. In 2023, CMS named 731 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Kandula for performance year 2024, reported through an alternative payment model (APM). Dr. Kandula accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kandula as offering telehealth.

Dmand AI links 14 papers to Dr. Kandula, published from 2010 to 2025. 2021 was the busiest year, with 2. The most frequent topics are Drug Resistant Epilepsy, Electroencephalography and Anticonvulsants. Dr. Kandula has published most often in Epilepsia. Dr. Kandula's most frequent co-authors are Maysaa Merhi Basha, MD, Krista Lynn Eschbach, MD and Elizabeth Erway Gerard, MD.

CMS Open Payments shows 47 general payments to Dr. Kandula from 11 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 56% of the total. Neuropace, Inc. paid the most, $4,964.

Dmand AI lists 1 award for Dr. Kandula, most recently CMS Stage 1 EHR in 2013.

Dr. Kandula graduated from Northeast Ohio Medical University in 1999.

Dr. Kandula is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.